Rhode Island Biotech EpiVax, Inc. Receives $500K Federal Grant to Reengineer FVIII using ''Immunoinformatics''

Published: Jun 27, 2007

PROVIDENCE, R.I.--(BUSINESS WIRE)--EpiVax, Inc, a leader the field of second generation protein therapeutics, announced today that it has received a grant to reengineer Factor VIII (FVIII), the primary therapeutic used to control bleeding for individuals who have acquired or hereditary hemophilia.

Back to news